LGEN:LSELegal & General Group Plc Analysis
Data as of 2026-06-14 - not real-time
£280.70
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
LGEN is trading at 280.7p, comfortably above its 20‑day (≈270p), 50‑day (≈262p) and 200‑day (≈253p) simple moving averages, indicating strong bullish momentum. The 14‑day RSI sits at 68, suggesting optimism but still below typical over‑bought thresholds. MACD shows a bullish crossover with the line (4.42) above the signal (3.79) and a positive histogram, reinforcing the upward bias. Price remains above the identified support at 258.2p and well under the 300p resistance, giving a healthy cushion. Volume trends are weakening, and 30‑day volatility is elevated at ~26%, implying price swings may intensify. The Fear & Greed Index reads “Extreme Greed” (89.9), reflecting strong market appetite for risk‑on assets like LGEN.
Fundamentally, revenue grew 14% YoY, yet margins are modest (gross 25%, operating 7%) and free cash flow is negative, raising concerns about cash generation. The dividend yield of 7.8% looks attractive, but a payout ratio above 260% is unsustainable. Valuation metrics are stretched: P/E of 35 versus an industry average of 17, and a price‑to‑book of 8.8, while the DCF model implies a fair value only modestly below current price, yielding a –6% upside/downside. Analyst consensus is neutral (hold) and Jefferies recently cut the rating to underperform with a 185p target, citing earnings pressure. Recent strategic moves, including £1.5bn of non‑core disposals and the £1.8bn sale of its U.S. protection business, aim to simplify the balance sheet and fund future growth. Combined, these factors suggest the stock is overvalued in the near term despite a supportive technical backdrop.
Fundamentally, revenue grew 14% YoY, yet margins are modest (gross 25%, operating 7%) and free cash flow is negative, raising concerns about cash generation. The dividend yield of 7.8% looks attractive, but a payout ratio above 260% is unsustainable. Valuation metrics are stretched: P/E of 35 versus an industry average of 17, and a price‑to‑book of 8.8, while the DCF model implies a fair value only modestly below current price, yielding a –6% upside/downside. Analyst consensus is neutral (hold) and Jefferies recently cut the rating to underperform with a 185p target, citing earnings pressure. Recent strategic moves, including £1.5bn of non‑core disposals and the £1.8bn sale of its U.S. protection business, aim to simplify the balance sheet and fund future growth. Combined, these factors suggest the stock is overvalued in the near term despite a supportive technical backdrop.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- Recent Jefferies downgrade and sub‑200p target
- Overvalued multiples relative to peers
- High dividend payout ratio unsustainable
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Ongoing asset disposals improving balance sheet
- Bullish technical positioning above key SMAs
- Potential for earnings stabilization after US protection sale
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Diversified insurance and asset‑management franchise
- Attractive dividend yield if payout ratio can be normalized
- Low beta indicating defensive characteristics in volatile markets
Key Metrics & Analysis
Financial Health
Revenue Growth13.90%
Profit Margin5.39%
P/E Ratio35.1
ROE17.86%
ROA0.11%
Debt/Equity2477.34
P/B Ratio8.8
Op. Cash Flow£4.5B
Free Cash Flow£-17395374080
Industry P/E16.8
Technical Analysis
TrendBullish
RSI67.8
Support£258.20
Resistance£300.00
MA 20£269.99
MA 50£261.98
MA 200£252.67
MACDBullish
VolumeDecreasing
Fear & Greed Index89.86
Valuation
Fair Value£9,971.51
Target Price£263.76
Upside/Downside-6.04%
GradeOvervalued
TypeBlend
Dividend Yield7.76%
Risk Assessment
Beta0.43
Volatility25.91%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.